Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Bitdeer Technologies Group (BTDR) vs Crispr Therapeutics AG (CRSP) Price & Performance

Bitdeer Technologies GroupTrade
Crispr Therapeutics AGTrade

Price performance (Past 24H)

Key statistics

Bitdeer Technologies Group vs Crispr Therapeutics AG — how do they compare? Bitdeer Technologies Group trades at $9.07 (market cap $2.36B), while Crispr Therapeutics AG trades at $54.31 (market cap $5.23B). The key difference: Crispr Therapeutics AG is far larger — about 2.2× Bitdeer Technologies Group's market cap, and Crispr Therapeutics AG is trading nearer its 52-week high, Bitdeer Technologies Group nearer its low. Which is the better fit depends on your goals.

BTDRCRSP
Market Cap
$2.36B$5.23B
Sector
TechnologyHealth
52-Week High
$25.90$76.78
52-Week Low
$7.28$44.34
Enterprise Value
$3.85B$3.65B

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Bitdeer Technologies Group

Bitdeer is a world-leading technology company for blockchain and high-performance computing. It provides comprehensive digital asset mining solutions, including cloud mining, hosting, and data center management.

Read more on BTDR

About Crispr Therapeutics AG

CRISPR Therapeutics is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. CRISPR's most advanced pipeline candidate, CTX001, is in collaboration with Vertex Pharmaceuticals and targets sickle cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is progressing additional gene editing programs for immuno-oncology, as well as a stem cell-derived therapy for the treatment of Type 1 diabetes.

Read more on CRSP